6-((3aS,7aR)-3-fluoro-pyridin-4-yl)-2-(hexahydro-2,4-dioxa-7-aza-inden-7-yl)-3-methyl-3H-pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-((3aS,7aR)-3-fluoro-pyridin-4-yl)-2-(hexahydro-2,4-dioxa-7-aza-inden-7-yl)-3-methyl-3H-pyrimidin-4-one
• 英文别名: 2-[(4aR,7aS)-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazin-4-yl]-6-(3-fluoropyridin-4-yl)-3-methylpyrimidin-4-one
• 化学式: C₁₆H₁₇FN₄O₃
• 分子量: 332.334
• InChiKey: LZPSMMDCTAIZFR-ZIAGYGMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  67.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氟吡啶 在 Carbonyldiimidazole 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 10.0h， 生成 6-((3aS,7aR)-3-fluoro-pyridin-4-yl)-2-(hexahydro-2,4-dioxa-7-aza-inden-7-yl)-3-methyl-3H-pyrimidin-4-one
  参考文献：
  名称：

  Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer’s disease

  摘要：

  We herein describe the results of further evolution of GSK-3 beta inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3 beta inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.005

文献信息

• 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES
  申请人：Fukunaga Kenji

  公开号：US20090233918A1

  公开（公告）日：2009-09-17

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R 2 represents a hydrogen or the like; R 3 represents methyl group or the like; R 20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R 4 represents hydrogen or the like; R 5 represents hydrogen or the like; R 6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH 2 , oxygen atom, NH, or the like; any one or more of R 5 and R 6 , R 5 and R 4 , R 6 and R 4 , X and R 5 , X and R 4 , X and R 6 , and R 6 and R 6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体或药物可接受的盐：其中，R2代表氢或类似物；R3代表甲基基团或类似物；R20代表卤素原子或类似物；q表示0到3的整数；Z代表氮原子，CH或类似物；R4代表氢或类似物；R5代表氢或类似物；R6代表取代的烷氧基或类似物；p表示0到3的整数；X代表键，CH2，氧原子，NH或类似物；R5和R6，R5和R4，R6和R4，X和R5，X和R4，X和R6以及R6和R6中的任何一个或多个可以结合形成环，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（例如阿尔茨海默病）。
• 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2423207A2

  公开（公告）日：2012-02-29

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R3 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  式 (I) 所代表的化合物、其光学活性异构体或其药用盐： 其中 R2 代表氢或类似物；R3 代表甲基或类似物；R20 代表卤原子或类似物；q 代表 0 至 3 的整数；Z 代表氮原子、CH 或类似物；R4 代表氢或类似物；R5 代表氢或类似物；R6 代表取代的烷氧基或类似物；p 代表 0 至 3 的整数；X代表键、CH2、氧原子、NH或类似物；R5和R6、R5和R4、R6和R4、X和R5、X和R4、X和R6、R3和R6中的任意一个或多个可相互结合形成环，用于预防和/或治疗由tau蛋白激酶1亢进引起的疾病，如神经退行性疾病（如阿尔茨海默病）。如阿尔茨海默病）。
• WO2007/119463
  申请人：——

  公开号：——

  公开（公告）日：——
• US8569294B2
  申请人：——

  公开号：US8569294B2

  公开（公告）日：2013-10-29
• Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer’s disease
  作者：Kenji Fukunaga、Daiki Sakai、Kazutoshi Watanabe、Kazuki Nakayama、Toshiyuki Kohara、Hiroshi Tanaka、Shinji Sunada、Mika Nabeno、Masako Okamoto、Ken-Ichi Saito、Jun-ichi Eguchi、Akiko Mori、Shinji Tanaka、Keiko Inazawa、Takashi Horikawa

  DOI：10.1016/j.bmcl.2015.01.005

  日期：2015.3

  We herein describe the results of further evolution of GSK-3 beta inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3 beta inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models. (C) 2015 Elsevier Ltd. All rights reserved.